HEADLINE SPONSOR

2

A very warm welcome to

The pharmaceutical industry, in its broadest sense, has positively transformed clinical outcomes for society in many diseases. Yet there are so many diseases for which we have made little or no progress to date, and many where real improvement is possible.

In recent years, we have seen an exponential growth in knowledge across the whole spectrum of areas from science to data handling. Our challenge is to harness this science to deepen our understanding of human biology, challenge the taxonomy of disease, and enhance clinical outcomes for patients such that society will appreciate the advance andreward the innovation.

A tall challenge when the near term shows the world still facing an austerity cycle.

Yet mankind wants progress and our ‘health’ is high on our individual priority list. This is obvious from the debate on access to healthcare in so many nations, from the increasing patient empowerment and engagement on the Internet and on social media, and the growth of the proportion of humanity that can make conscious economic decisions on their own health and welfare.

The industry and all its partners need to understand the trends, the power of science, big data and modern management approaches and the development of skills and leadership required across the value chain. This will be the way to ensure we deliver future products and services that positively move the ‘needle of medicine’ in a way that can meet all our stakeholders’ requirements.

The Pharma Integrates 2015 conference is your opportunity to participate in the debate on how to shape pharma’s future and to enrich your own contribution to your sphere of influence.

I would like to thank all who have helped make this conference possible, from the organisers to the new, and the loyal sponsors for their generous support, and to the speakers for their thoughtful input to the programme.

Finally I would like to thank all attendees for their presence. I hope that you enjoy the experience and benefit from participating.

W.M. BurnsEvent Chair & Former Chief Executive Officer, Roche Pharmaceuticals

3

Panellists include

Bil l BurnsEvent Chair & Former Chief Executive OfficerRoche Pharmaceuticals

Cornel l StamoranVice President, Corporate StrategyCatalent Pharma Solutions

Aisl ingBurnandMBEChief Executive OfficerAssociation ofMedical ResearchCharities

Ted SmithDirector of People & FacilitiesThe Wellcome Trust

Jo PisaniPartner,Pharmaceuticals &Lifesciences StrategyStrategy &PricewaterhouseCoopers

Alex RobertsonSenior Director, Supply Chain ManagementAstraZeneca

Sir Peter LachmannEmeritus Professor of ImmunologyUniversity of Cambridge

Ian MoulesSenior Director, Search & Evaluation Centre for External InnovationTakeda Pharmaceuticals

Kathrin BrodowskiHead Diabetes Portfolio Management & Deputy Strategy and Portfolio ManagementSanofi

TommyDolanVice President Drug Product Design and Supply Worldwide R&DPfizer

Pete Mil l iganVice President Clinical Platforms TransformationGlaxoSmithKline

Carl FirthChief Executive OfficerAslan Pharmaceuticals

Michael HuntChief Financial OfficerReNeuron

Peter ComesCorporate Vice President Supply Network StrategyBoehringer Ingelheim

Amanda WhiteDirector International Employee RelationsAbbVie

Des HoldenMedical DirectorSurrey & Sussex Healthcare NHS Trust

Stephen SimpsonDirector of ResearchArthritis Research UK

Maureen ColemanExecutive ChairmanCN BioInnovations

RichardBarker OBEDirectorCentre for the Advancement of Sustainable Medical Innovation

Michele ActonChief ExecutiveFight for Sight

Robert DunlopManaging Director Almac Clinical ServicesAlmac Group

Ronald OpenshawChief Executive OfficerSimbec-Orion Group

John BeadleChief Executive OfficerPsiOxus Therapeutics

Steve FacerSenior Vice President EMEACapsugel

Andrew FriedLife Sciences EuropeDirectorIBM

Roberto MargaritaDirector Global Antibiotics & Oncology PlatformsCordenPharma

Duncan McHaleVice President Global Exploratory DevelopmentUCB Pharma

Nick StephensExecutive ChairmanRSA

Lode DewulfChief Patient Affairs OfficerUCB Pharma

Sharon JohnsonSenior Vice President, Quality, Product Development & Regulatory AffairsCatalent Pharma Solutions

Serkan OraySenior Director, Device & TechnologyUCB Pharma

Chris MolloyChief Executive OfficerRSA Group

Ian MuirManaging DirectorAesica Pharmaceuticals

Line LystHead of QualityCare Strategy & PlanningLEO Pharma

Mark CassidyPresident API ServicesPiramal Healthcare

Steve BarrVice President, Business Development Europe, Fine ChemicalsJohnson Matthey

Panellists include

4

Eliot ForsterChief Executive Officer, Immunocore& Executive ChairMedCity

Arjan AdegeestDirector CMO OperationsMerck Serono

Anne HancockChief Operating OfficerTranScrip Partners

Ewan LiveseySenior Vice President M&A and Specialty Business DevelopmentLupin

Karsten BrandtHead of Market Development, Europe and AsiaStratum Nutrition

Georg BuchnerLicensing Director Europe & IsraelAmgen

Michelle FoustDirector of Supply Chain Strategy- Clinical ServicesAlmac

Wil l iam SpoonerChief Science OfficerEagle Genomics

Mike HannayGeneral ManagerFisher Clinical Services

Jacqui CooksonManaging DirectorVolantis

Tina FlatauManaging DirectorBiopharma Projects

Peter NolanChief Business OfficerOxford BioMedica

Jonathan AbrahamChief Executive OfficerHealum

Howard MarriageTranslator and Entrepreneur in ResidenceThe Francis Crick Institute

Chris DowleDirector of BiologicsThe Centre for Process Innovation

Jagjit Singh SraiHead, Centre for International ManufacturingUniversity of Cambridge

Marco SardinaResearch & Development DirectorZambon Pharma

Oliver TimmisHead of ProjectsAKU Society

Matthew BonamDirector, Intelligent PharmaceuticalsAstraZeneca R&D

Gregor KawaletzChief Commercial OfficerIDT Biologika

Christopher BlandExecutive Director, Head of Formulation TechnologiesBayer Healthcare - Animal Health

Loy LoboMember, Telemedicine and eHealth CouncilRoyal Society of Medicine

MichaelO’BrienVice President Pharmaceutical Sciences Technology & Innovation GroupPfizer

David HarrisonDirector, Manufacturing AlliancesUCB Pharma

Clive BadmanHead PTSPre-Competitive ActivitiesGlaxoSmithKline

Eddy Litt lerChief Executive OfficerDomainex

Iain UingsDirector, Discovery Partnerships with AcademiaGlaxoSmithKline

Lizzie TuckeyMedical DirectorBupa UK

Jonathan BlameyVice President Solution Design Life Sciences & HealthcareDHL Supply Chain

Lee ConeyChief Scientific OfficerEnvigo

Phi l ip SheringAssociate Engineering DirectorAstraZeneca

Al i PriceManaging DirectorSunningdale Computers

12:00 – 14:00 Registration and Networking Refreshments

14:00 – 14:20 Chairperson’s welcome and opening remarks with Bill Burns.

14:20 – 15:20 Loading the Development Dice: Encouraging Stakeholder EngagementAn integrated healthcare ecosystem means that patients can take more responsibility for their own health, doctors can diagnose and treat rural patients remotely, medical errors are reduced, administration is improved, cost savings can be made and caregivers are able to give better informed decisions, which enhances the overall quality of care.The early engagement of regulators and payers in the pharmaceutical development process is critical to creating a value circle. The lag between pipeline development and profit, and the compression of development timeframes need to be addressed. Can the pharmaceutical industry continue to play a zero sum game and what does the future look like if the outcomes are only win or lose? Are adaptive trials part of the solution? And, at what stage does engagement become crucial: pre-, post- or during research and development?

Panellists include: Richard Barker OBE, Director, CASMI; Eliot Forster, Executive Chair, MedCity &Chief Executive Officer, Immunocore; Ronald Openshaw, Chief Executive Officer, Simbec-Orion Group;Matthew Bonam, Director, Intelligent Pharmaceuticals, AstraZeneca R&D

Facilitated by:Bill Burns, Event Chair & former Chief Executive Officer, Roche Pharmaceuticals

15:20 – 15:50 Networking Refreshment Break

Agenda Day One 17 November 2015

5

15:50 – 16:50 Optimizing the Product-Performance Model

With a focus on outcomes, performance and services, as well as products, panellists will explore how the pharmaceutical industry needs to move faster, evolve and assume its own risk, rather than being managed by regulators. From a manufacturing perspective, reducing process diversity, improving technology transfer and audit standards are on the agenda, as are technologies to improve adherence/compliance and models that combine diagnostics with medication.The use of remote monitoring technologies, wearable devices and real-world evidence to increase our understanding of patient benefit in clinical practice will also be discussed.

Panellists include: Tommy Dolan, Vice President Drug Product Design and Supply Worldwide R&D, Pfizer;Duncan McHale, Vice President Global Exploratory Development, UCB Pharma; Cornell Stamoran, Vice President Corporate Strategy, Catalent Pharma Solutions; Roberto Margarita, Director Global Antibiotics & Oncology Platforms, Corden Pharma

Facilitated by: Jo Pisani, Partner Pharmaceuticals & Life Sciences, Strategy& PricewaterhouseCoopers

16:50 – 17:50 The Myths, Successes and Challenges of Pre-Competitive Collaboration

Panellists will discuss the drivers of pharmaceutical pre-competitive collaboration and any ongoing initiatives, what successes they’ve experienced and the key parameters that led to achieving those goals. Also to be discussed:the main challenges. What are the hurdles, both real and imagined, how can we address them and what areas shouldwe be working on? Could examples such as the TransCelerate experience drive further collaboration across the life science sector? Join the debate and find out.

Panellists include: Pete Milligan, Vice President Clinical Platforms Transformation, GlaxoSmithKline;Jag Srai, Head Centre for International Manufacturing, University of Cambridge;Philip Shering, Associate Engineering Director, AstraZeneca; Michael O’Brien, Vice President Pharmaceutical SciencesTechnology & Innovation Group, Pfizer Chris Dowle, Director of Biologics, The Centre for Process Innovation

Facilitated by: Alex Robertson, Senior Director Supply Chain Management, AstraZeneca

17:50 – 19:30 Networking Champagne Reception

6

Introducing Our Sponsors 2015

Headline Sponsor

Platinum Sponsors

Gold Sponsors

7

Conference Badge Sponsor

Silver Sponsors

8

Agenda Day Two 18 November 2015

Track 108:30 – 08:55 Coffee & Pastries

09:00 – 10:00Grass Roots Innovation: Collaborative Thinkingfor Improved R&D

Enhanced R&D productivity is a key challenge for pharmaceutical manufacturers. Grassroots innovation programmes — structured processes aimed at stimulating employees in all corners of the organization to contribute to innovation efforts — may be an essential complement to pharmaceutical firms’ more traditional and top-down stage gate processes.However, academic research to guide pharmaceutical firms in the implementation of grassroots innovation is scarce. Is there a solution? Advances have been made through computer-aided drug design, high-throughput techniques and the omics revolution. But, what’s next?Both small and large companies are racing to bring game-changing therapies to the market and, in many cases, partnering to maximize on combination therapies. As a result, innovative approaches and developments are also creating increased momentum for investment/business development opportunities. Should we take a leaf out of the book on immunotherapy?

Panellists Include: Lee Coney, Chief Scientific Officer, Envigo; Ian Moules, Senior Director Search & Evaluation Centre for External Innovation, Takeda Pharmaceuticals; Peter Nolan, Chief Business Officer, Oxford BioMedica; William Spooner, Chief Science Officer, Eagle Genomics;Howard Marriage, Translator and Entrepreneur in Residence, The Francis Crick Institute

Facilitated by:Iain Uings Director DiscoveryPartnerships, Academia, GlaxoSmithKline

10:05 – 11:05Financing Pharmaceutical Development:The Chicken and Egg Debate

Highlighting the importance of the link between the patient, technology and funding, this session will focus on closing the pharmaceutical funding gap and pose the question: does adequate funding result in successful biotech development, or does positive research stimulate financial support? Can researchers and companies work together to bring their innovations to market without external funding, or is biotechnology R&D success simply a product of the right amount of investment? Is capitalizing on inventiveness and resourcefulness enough for market success?

Panellists Include: Michael Hunt, Chief Financial Officer, ReNeuron; Carl Firth, Chief Executive Officer, Aslan Pharmaceuticals; Georg Buchner, Licensing Director Europe & Israel, Amgen; Michele Acton, Chief Executive, Fight for Sight

Facilitated by:John Beadle, Chief Executive Officer, PsiOxus Therapeutics

11:05 – 11:35 Networking Refreshment Break

Track 208:30 – 08:55 Coffee & Pastries

09:00 – 10:00Accelerating Product Development: From Innovation to Commercialisation

In recent years, the pharmaceutical industry has faced declining R&D productivity, a rapidly changing healthcare landscape and fierce competition from generics, resulting in lower growth and profit margins. One meaningful and holistic approach to today’s current challenges is to focus on product lifecycle management (PLM). In recent years, PLM has provided many pharmaceutical organizations with the ability to get products to market quicker, ensure greater regulatory compliance and efficiencies while reducing development costs. But is it enough? Open innovation may be too slow, new technology is often poorly understood by industry leaders and identifying appropriate partners to fully exploit developments can be challenging. How can the pharmaceutical industry exploit this innovation?

Panellists Include: Kathrin Brodowski, Head Diabetes Portfolio Management & Deputy Strategy and Portfolio Management, Sanofi; Sharon Johnson, Senior Vice President Quality, Product Development & Regulatory Affairs, Catalent Pharma Solutions; Sir Peter Lachmann, Emeritus Professor of Immunology, University of Cambridge

Facilitated by:Michael O’Brien, Vice President Pharmaceutical Sciences Technology & Innovation Group, Pfizer

11:05 – 11:35 Networking Refreshment Break

10:05 – 11:05Disruption and Pharmaceutical Conservatism

We are surrounded by disruption. It causes chaos, stimulates innovation, results in failed companies and produces new products, processes, industries and leaders. The healthcare sector and pharma industry have a reputation for being conservative and citing heavy regulation to justify the slow pace of change. Yet to survive and flourish we need to be responsive to the changing environment and to devise new ways of providing patients with improved health outcomes at a fraction of today’s cost. Some political leaders are asking what it might take to deliver high quality healthcare at 1% of GDP.What can we learn from other industries? Do we sit back and let others take the lead then follow? Is it new technologies or new processes that will lead the way to sustained, better healthcare? How do we respond to Precision Medicine, Personalised Medicine, and the quest for affordable healthcare?With their disparate backgrounds – some steeped in many years working in the pharma industry others new to the sector – the panel hope to stimulate discussion on the issues facing us all.

Panellists Include: Jonathan Abraham, Chief Executive Officer, Healum; Serkan Oray, Senior Director Device Technology, UCB Pharma; Anne Hancock, Chief Operating Officer, TranScrip Partners; Loy Lobo, Member, Telemedicine and eHealth Council, Royal Society of Medicine & Visiting Lecturer, Imperial College Business School

Facilitated by:Maureen Coleman, Executive Chairman, CN BioInnovations

9

Agenda Day Two 18 November 2015

Track 111:35 – 12:35Patient Power: Putting the “End-User” First

Enabling patients to live happier, healthier lives is fundamental to the pharmaceutical industry; it’s a common goal, shared by healthcare providers, governments and/or insurance-funded private providers. As such, listening to the patient and focusing on outcomes must improve decision making, product development and innovation. The co-creation of products with patients and doctors is already happening. Patient and advocacy groups are finally being heard at outcomes meetings and NICE committees. But, how does the pharmaceutical industry use the input and even if it results in enhanced technology, who’s going to cover the costs? How do we ensure that enhanced end-user/patient outcomes are properly valued by the payers, especially with existing therapies?

Panellists Include: Lode Dewulf, Chief Patient Affairs Officer, UCB Pharma;Des Holden, Medical Director, Surrey & Sussex Healthcare NHS Trust; Lizzie Tuckey, Medical Director, BUPA UK; Line Lyst, Head of QualityCare Strategy & Planning, LEO Pharma

Facilitated by:Tina Flatau, Managing Director, Biopharma Projects

13:35 – 14:35Big Data: Real-World Applications forEnhanced Drug Development

From research records and patient information to utilization details and supply chain monitoring, pharmaceutical firms have been managing vast amounts of data for years. However, as in virtually every industry, the era of big data has led to explosive growth in the volume, variety and complexity of information. A key issue remains, though. It’s not just about data collection, but determining what’s useful and how to use it.Taking a more evidence-based and data-driven approach would take manufacturers and CROs beyond reporting, analytics and KPI-based metrics to modelling drug development and simulating clinical studies, leveraging their big data warehouses to enhance patient recruitment and supply chain management (JIT product shipping), and even improve the probability of successfully developing a drug using outcomes based on protocol design, real world data and acceptability to the patient, investigators, regulatory agencies and payers. Such practices would offer higher levels of confidence and security for trial sponsors, engender more trust between pharmaceutical companies and CROs. And, overall, increase patient safety.

Panellists Include: Aisling Burnand MBE, Chief Executive Officer, Association of Medical Research Charities; Chris Molloy, Chief Executive Officer, RSA Group;Andrew Fried, Life Sciences Europe – Director, IBM; Ali Price, Managing Director, Sunningdale Computers

Facilitated by:Jo Pisani, Partner Pharmaceuticals & Life Sciences, Strategy& PricewaterhouseCoopers

12:35 – 13:35 Networking Luncheon

Track 211:35 – 12:35Rebuilding Contract Pharma

In an atmosphere of declining R&D productivity, mounting pricing pressure and changing regulatory requirements, global pharmaceutical companies face increasing challenges to achieve and maintain profitable growth. Outsourcing offers companies an opportunity to face these challenges. Yet, CMOs and CROs have grown up with the blockbuster model, which is no longer relevant. Does the established model accurately reflect today’s requirements and what would a brand new solution look like? What are the current critical issues in clinical development, manufacturing and commercial supply chains? The providers believe full service and scale are key, but is this the case? Is everything as it should be and who’s setting the M&A agenda?

Panellists Include: Steve Facer, Senior Vice President EMEA, Capsugel; Steve Barr, Vice President Business Development Europe Fine Chemicals, Johnson Matthey; Gregor Kawaletz, Chief Commercial Officer, IDT Biologika; Christopher Bland, Executive Director Head of Formulation Technologies, Bayer Healthcare – Animal Health; Ian Muir Managing Director, Aesica Pharmaceuticals

Facilitated by:Mike Hannay, General Manager, Fisher Clinical Services

12:35 – 13:35 Networking Luncheon

13:35 – 14:35Supply Chain: Moving from a Stock-Based to anOrder-Based Model?

As scientific advances enable the industry to move from a ‘one-size-fits-all’ approach to healthcare, to one of segmentation, personalization and wellness, so the supply chain will need to evolve. The supply chain of the future will be built around flexibility, responsiveness and reliability, shifting the supply paradigm from a stock-based model to an order-based one. But how do we get there? Issues include building supply chains for the future of pharma, forecasting versus replenishment, taking a discovery to patient approach and the trend towards smaller product volumes for specific markets where replenishment may be the best way forward.

Panellists Include: Alex Robertson, Senior Director Supply Chain Management, AstraZeneca; Jonathan Blamey, Vice President Solution Design Life Sciences & Healthcare, DHL Supply Chain; Michelle Foust, Director of Supply Chain Strategy Clinical Services, Almac; Olivier Riou, Vice President Supply Chain Europe, Russia & CIS, Lupin

Facilitated by:Robert Dunlop, Managing Director, Almac Clinical Services

10

Agenda Day Two 18 November 2015

Track 114:40 – 15:40Creating and Protecting a Patient-Centric Value Strategy

As the pharmaceutical industry increasingly embraces patient-centric health outcomes, simply supplying a pill is no longer enough. Individual companies and alliances must engage and deliver patient-focused services and strategies that, at the same time, provide a source of reliable end-user data and address issues such as improving compliance.The pharmaceutical industry must change its focus — integrating diagnostics, mHealth and the patient, and highlight outcomes as opposed to the product itself.Can contracting/deal making and collaboration be made easier between SMEs, academia and the greater life science community? How should industry (and its partners e.g. medical funders and charities) build the next steps for trust/engagement and importantly involvement of patients in all areas of activity? How do we stop IP being a barrier as opposed to an enabler?Can the industry “up its game” and change its culture to really put patients at the very centre of research? How much is really feasible: what are the opportunities and what are the constraints?

Panellists Include: Marco Sardina, Research & Development Director, Zambon Pharma;Eddy Littler, Chief Executive Officer, Domainex; Karsten Brandt, Head of Market Development Europe & Asia, Stratum Nutrition;Stephen Simpson, Director of Research, Arthritis Research UK;Oliver Timmis, Head of Projects, AKU Society

Facilitated by:Ewan Livesey, Senior Vice President M&A and Specialty Business Development, Lupin

Track 214:40 – 15:40Advanced Manufacturing – Moving the Contracting Relationships On?

There has been a recent focus in developing continuous manufacturing and other manufacturing techniques with the promise of reduced costs of goods, reduced capital expenditure and faster lead times but also speeding up the advance to personalised medicines. In many of these areas the pharma industry is lagging behind other industries such as petrochemicals and consumer products where continuous manufacturing has been well established.The debate is being led by the pharma companies and we do not yet see contract manufacturers take a strong lead in developing technologies and promoting their adoption. Why is this? Is it that process innovation needs to be customer led? Or do the financials of many CMO players mean there is limited headroom to invest and drive innovation?

Panellists Include: Clive Badman, Head PTS Pre-Competitive Activities, GlaxoSmithKline; Jag Srai, Head Centre for International Manufacturing, University of Cambridge; Peter Comes, Corporate Vice President Supply Network Strategy, Boehringer Ingelheim; Arjan Adegeest, Director CMO Operations, Merck Serono; Mark Cassidy, President API Services, Piramal Healthcare

Facilitated by:David Harrison, Director Manufacturing Alliances, UCB Pharma

15:40 – 16:00 Networking Coffee Break

16:00 – 17:00The People Ingredient: Mapping Pharma’s Future

The pharmaceutical industry is one of the largest, most enduring and knowledge-intensive sectors in the global economy and it is one that touches all our lives. Unlike many other sectors Pharma’s R&D productivity has declined year-on-year, development costs have risen and new drug registrations have focussed on smaller patient populations. Like everyone else it has also been affected by the economic crisis and been forced to rethink its strategy to remain competitive.As a result leaders in our sector recognise the need to change their approach and to adapt their hiring and development goals to address an uncertain future. Surviving and thriving in a changing world, branding, collaboration, diversity, culture and retention are all up for debate.

Panellists Include: Ted Smith, Director of People & Facilities, Wellcome Trust; Amanda White, Director International Employee Relations, AbbVie;Jacqui Cookson, Managing Director, Volantis

Facilitated by:Nick Stephens, Executive Chairman, RSA

15:40 – 16:00 Networking Coffee Break

16

About Life Sciences Index

Life Sciences Index (LSI) is a leading provider of debate-led events for senior executives and decision makers in the greater life science industries - pharmaceutical, nutraceutical, health and nutrition - to network, learn, share knowledge and resolve critical business issues.

Established in 2011 and embraced by sponsors, delegates and speakers alike, LSI’s unique approach has resulted in a growing portfolio of highly successful events, including Pharma Integrates and Nutrition Integrates, launched in 2011 and 2014, respectively.

Bringing together subject matter experts from a variety of global businesses, functions and geographical locations to examine the drivers and hurdles of today and address those of tomorrow, founders Christopher Watt and Samuel Thangiah have combined many years of business-to-business event, conference and digital community experience to enable market leaders to stay current and connected.

LSI’s mission is to provide key sector stakeholders with a series of interactive platforms for rigorous and ongoing peer-to-peer discussion and a productive environment in which to network, learn and share knowledge.

Introducing Nutrition Integrates 2016

Now firmly established as a must-attend event in the functional food and nutraceutical calendar, Nutrition Integrates returns to London on 6 June 2016 to promote debate and discussion amongst senior level strategists from the nutrition and wider business communities.

Taking a closer look at the business and technology of nutraceuticals, Nutrition Integrates 2016 is all about a healthier world, developing functional products and progressing them from concept to application. Panellists will discuss strategy, trends and innovation in the functional food, ingredients and health industries, and cover topics including dosage forms and delivery, claim substantiation, outsourcing, new product development, the microbiome, marketing strategies and more. Further agenda details will be released shortly. For more information, visit www.lifesciencesindex.com

Life Sciences Index LimitedSuite 1, 4th FloorAMP House, Dingwall RoadSurrey CR0 2LXUnited Kingdom

MEDIA PARTNERS

www. l i fesc iences index.com

Introducing LSI Talent Acquisition

LSI Talent Acquisition is a specialist recruitment consultancy for the pharmaceutical, nutraceutical, health and nutrition sectors that takes an integrated approach to providing global solutions that meet your recruitment objectives.

Offering an exceptional service to candidates and clients alike, our experienced consultants are able to leverage an established network of global relationships and contacts to deliver high quality executive headhunting solutions to organisations in our chosen sectors.

Our goal is to find qualified business professionals who are technically literate, globally astute and operationally agile. Our services also include permanent/interim staff placement, executive searches, testing and training. For more information, visit www.lifesciencesindex.com